Trial Profile
Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jan 2020
Price :
$35
*
At a glance
- Drugs RGX 501 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- 09 Jan 2020 Results published in REGENXBIO media release.
- 09 Jan 2020 According to a REGENXBIO media release, Interim update from RGX-501 Phase I/II trial in HoFH supports Cohort 2 safety with steroid prophylaxis; LDL-C measures expected in 1H 2020
- 05 Nov 2019 According to a REGENXBIO media release, dosing has been completed in cohort 2 of this study. Interim results are expected at the year end.